TY -的T1 -评价anti-LGI1癫痫治疗的anti-NMDAR,和anti-GABABbR脑炎(S11.008) JF -神经学乔-神经学六世- 92 - 15补充SP - S11.008盟Marienke De Bruijn 首页AU -艾格尼丝·Sonderen AU -玛莲Van Coevorden-Hameete盟安娜Rob Rouhl Bastiaansen AU -马可Schreurs盟盟齐斯·范Donselaar AU -玛丽安Majoie盟Rinze Neuteboom盟——彼得Sillevis Smitt AU -罗兰Thijs盟Maarten Titulaer Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_Supplement/S11.008.abstract N2 -目的:评估响应的癫痫患者的免疫治疗和抗癫痫药物(aed) anti-leucine-rich glioma-inactivated 1 (LGI1) anti-N-Methyl-D-Aspartate受体(NMDAR)和anti-Gamma-Aminobutyric-Acid-B受体(GABABR)脑炎,描述慢性癫痫的风险。背景:癫痫发作频繁发生自身免疫性脑炎(AIE)。发作通常似乎对aed,同时对免疫疗法的反应是很好的。然而,没收自由并不总是实现在使用免疫疗法和aed有时需要。然而,目前尚不清楚aed在这些患者是安全的,如果他们是有效的,aed应该优先。设计/方法:最近诊断为癫痫患者和anti-LGI1 anti-GABABR或anti-NMDAR脑炎是包含在这个全国性的队列研究。疾病医疗信息,类型的aed和免疫疗法使用,效果和副作用收集。结果措施:1)没收自由达到在使用aed,虽然使用免疫治疗,2)天没收自由从开始aed和免疫治疗,3)慢性癫痫的发展,和4)报道的副作用。结果:153年AIE病人(53 LGI1;75 NMDAR;25 GABABR), 72% (n = 110)有癫痫,89%达到夺取自由。至少53%达到夺取自由免疫治疗后不久,和14%达到夺取自由只在使用aed(术中,0.0001)。 Median time to seizure freedom from AEDs start was 59 days (IQR 27–160), and 28 days from start of immunotherapy (IQR 9–71, p<0.0001). Carbamazepine was more effective than levetiracetam in reducing seizures in anti-LGI1 encephalitis (p=0.031). Only one patient, of 86 surviving patients, developed chronic epilepsy.Conclusions: Seizure freedom is achieved faster and more frequently after immunotherapy than after AEDs in patients with anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. AEDs should be considered as add-on therapy, and similar to treatment of other encephalitis symptoms, immunotherapy is most crucial. Chronic epilepsy is rare in adequately treated AIE.Disclosure: Dr. De Bruijn has nothing to disclose. Dr. Van Sonderen has nothing to disclose. Dr. van Coevorden-Hameete has nothing to disclose. Dr. Bastiaansen has nothing to disclose. Dr. Schreurs has nothing to disclose. Dr. Rouhl has nothing to disclose. Dr. van Donselaar has nothing to disclose. Dr. Majoie has nothing to disclose. Dr. Neuteboom has nothing to disclose. Dr. Sillevis Smitt has nothing to disclose. Dr. Thijs has nothing to disclose. Dr. Titulaer has received research support from MedImmune LLC., Guidepoint LLC. ER -